reports
Madrigal Pharmaceuticals Inc: 1 director
A director at Madrigal Pharmaceuticals Inc sold 3,400 shares at 350.302USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcomi...
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday, November 13, 2024 at 2:00 P.M. ESTThe presentation will be webcast live and may be accessed . 7th Annual Evercore HealthCONx ConferenceWednesday, December 4, 2024 at 9:35 A.M. EST Piper Sandler 36th Annual Healthcare ConferenceThursday, ...
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results ...
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at...
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) A...
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego. Bill Si...
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Stu...
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomesStudy may also support full approval of RezdiffraTM (resmetirom) in noncirrhotic NASH CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delive...
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Resul...
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section...
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8...
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024. The fireside chat will be webcast live and may be accessed or by visiting Madrigal’s website’s Investor Relations Events . A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Ma...
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vi...
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Deve...
Madrigal Pharmaceuticals Announces Publication of Positive Health-Rela...
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distressStudy results underscore the positive tolerability profile of Rezdiffra CONSHOHOCKEN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohe...
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22...
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET. The presentation will be webcast live and may be accessed or by visiting Madrigal’s Investor Relations Events . A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceutic...
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results...
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsyExpert guidelines recommend Rezdiffra as first-line therapy for patients with F2/F3 NASH/MASHPlans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion at June 30, 2024Co...
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Off...
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Resu...
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of th...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Rotation is the Lifeblood of a Bull Market Semiconductors (SMH, SOXX, NVDA, AVGO, etc.) have been leadership since late-2022, but they are extended and are starting to see some profit taking as market participants rotate into other areas of the market that have been lagging (especially Energy, and to a lesser extent banks and small-caps). The question is whether this new trend lasts a few days, or if this is the start of longer-term trend. We would not be surprised to see more consolidation for...
WM WASTE MANAGEMENT INC.
TTEK TETRA TECH INC.
TJX TJX COMPANIES INC
ROST ROSS STORES INC.
ROL ROLLINS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
ITCI INTRA-CELLULAR THERAPIES INC.
HALO HALOZYME THERAPEUTICS INC.
CLH CLEAN HARBORS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
IONS IONIS PHARMACEUTICALS INC.
RSG REPUBLIC SERVICES INC.
UTHR UNITED THERAPEUTICS CORPORATION
WCN WASTE CONNECTIONS INC.
MDGL MADRIGAL PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
PCVX VAXCYTE
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-N...
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved...
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annu...
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET. The presentation will be webcast live and may be accessed or by visiting Madrigal’s website’s Investor Relations Events . A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madri...
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) a...
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. “The data we will be presenting at EASL further support Rezdiffr...
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results ...
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn April 2024, product shipped and first patients received Rezdiffra, the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)On March 5, 2024, announced validation of European Medicines Agency marketing application for resmetirom Raised $690 million in gro...
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal Statement on the Passing of Dr. Stephen Harrison CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent innovations and achievements we’ve se...
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Resul...
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Mad...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.